Annual CFO
-$21.07 M
-$3.12 M-17.37%
December 31, 2023
Summary
- As of February 21, 2025, ONCY annual cash flow from operations is -$21.07 million, with the most recent change of -$3.12 million (-17.37%) on December 31, 2023.
- During the last 3 years, ONCY annual CFO has fallen by -$4.60 million (-27.92%).
- ONCY annual CFO is now -5757.27% below its all-time high of -$359.70 thousand, reached on December 31, 1999.
Performance
ONCY Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
September 30, 2024
Summary
- ONCY quarterly cash flow from operations is not available.
Performance
ONCY Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
September 30, 2024
Summary
- ONCY TTM cash flow from operations is not available.
Performance
ONCY TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ONCY Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.4% | - | - |
| 3 y3 years | -27.9% | - | - |
| 5 y5 years | -129.1% | - | - |
ONCY Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -17.8% | at low | ||||
| 5 y | 5-year | -40.5% | at low | ||||
| alltime | all time | -5757.3% | +38.5% |
Oncolytics Biotech Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$21.07 M(+17.4%) | -$4.43 M(-1.9%) | -$21.07 M(-0.8%) |
| Sep 2023 | - | -$4.52 M(-28.5%) | -$21.25 M(+7.5%) |
| Jun 2023 | - | -$6.33 M(+9.3%) | -$19.76 M(+5.1%) |
| Mar 2023 | - | -$5.79 M(+25.4%) | -$18.80 M(+4.8%) |
| Dec 2022 | -$17.95 M(+0.3%) | -$4.61 M(+52.1%) | -$17.95 M(-2.7%) |
| Sep 2022 | - | -$3.03 M(-43.6%) | -$18.45 M(+1.8%) |
| Jun 2022 | - | -$5.37 M(+8.9%) | -$18.13 M(-1.6%) |
| Mar 2022 | - | -$4.93 M(-3.5%) | -$18.43 M(+3.0%) |
| Dec 2021 | -$17.89 M(+8.6%) | -$5.11 M(+88.4%) | -$17.89 M(+5.3%) |
| Sep 2021 | - | -$2.71 M(-52.2%) | -$16.99 M(-11.4%) |
| Jun 2021 | - | -$5.68 M(+29.2%) | -$19.17 M(+7.0%) |
| Mar 2021 | - | -$4.39 M(+4.3%) | -$17.91 M(+8.8%) |
| Dec 2020 | -$16.47 M(+9.8%) | -$4.21 M(-13.9%) | -$16.47 M(-6.8%) |
| Sep 2020 | - | -$4.89 M(+10.7%) | -$17.68 M(+8.5%) |
| Jun 2020 | - | -$4.42 M(+49.8%) | -$16.29 M(+5.7%) |
| Mar 2020 | - | -$2.95 M(-45.6%) | -$15.40 M(+2.7%) |
| Dec 2019 | -$15.00 M(+63.1%) | -$5.42 M(+55.0%) | -$15.00 M(+15.2%) |
| Sep 2019 | - | -$3.50 M(-1.0%) | -$13.02 M(+7.0%) |
| Jun 2019 | - | -$3.53 M(+38.8%) | -$12.16 M(+50.2%) |
| Mar 2019 | - | -$2.55 M(-26.0%) | -$8.09 M(-12.0%) |
| Dec 2018 | -$9.20 M(-19.9%) | -$3.44 M(+30.3%) | -$9.20 M(+15.9%) |
| Sep 2018 | - | -$2.64 M(-594.5%) | -$7.94 M(-4.2%) |
| Jun 2018 | - | $534.30 K(-114.6%) | -$8.29 M(-31.8%) |
| Mar 2018 | - | -$3.65 M(+67.2%) | -$12.16 M(+5.8%) |
| Dec 2017 | -$11.49 M(+21.9%) | -$2.18 M(-27.1%) | -$11.49 M(-4.9%) |
| Sep 2017 | - | -$2.99 M(-10.2%) | -$12.08 M(+6.4%) |
| Jun 2017 | - | -$3.34 M(+11.9%) | -$11.36 M(+11.3%) |
| Mar 2017 | - | -$2.98 M(+7.3%) | -$10.20 M(+8.2%) |
| Dec 2016 | -$9.42 M(-20.0%) | -$2.78 M(+22.5%) | -$9.42 M(-7.9%) |
| Sep 2016 | - | -$2.27 M(+4.0%) | -$10.23 M(+4.8%) |
| Jun 2016 | - | -$2.18 M(-1.1%) | -$9.76 M(-17.0%) |
| Mar 2016 | - | -$2.20 M(-38.5%) | -$11.76 M(-0.1%) |
| Dec 2015 | -$11.78 M(-33.9%) | -$3.58 M(+99.3%) | -$11.78 M(+7.2%) |
| Sep 2015 | - | -$1.80 M(-57.0%) | -$10.99 M(-17.2%) |
| Jun 2015 | - | -$4.18 M(+88.3%) | -$13.27 M(-8.2%) |
| Mar 2015 | - | -$2.22 M(-20.7%) | -$14.45 M(-18.9%) |
| Dec 2014 | -$17.82 M(-24.9%) | -$2.80 M(-31.4%) | -$17.82 M(-8.5%) |
| Sep 2014 | - | -$4.08 M(-23.9%) | -$19.48 M(-9.3%) |
| Jun 2014 | - | -$5.36 M(-4.2%) | -$21.47 M(+2.3%) |
| Mar 2014 | - | -$5.59 M(+25.5%) | -$20.98 M(-11.6%) |
| Dec 2013 | -$23.73 M(-30.7%) | -$4.45 M(-26.6%) | -$23.73 M(-8.4%) |
| Sep 2013 | - | -$6.07 M(+24.6%) | -$25.91 M(-7.4%) |
| Jun 2013 | - | -$4.87 M(-41.7%) | -$27.97 M(-18.0%) |
| Mar 2013 | - | -$8.35 M(+26.0%) | -$34.13 M(-0.4%) |
| Dec 2012 | -$34.27 M(+50.3%) | -$6.63 M(-18.5%) | -$34.27 M(-1.4%) |
| Sep 2012 | - | -$8.13 M(-26.3%) | -$34.76 M(+4.6%) |
| Jun 2012 | - | -$11.02 M(+29.9%) | -$33.25 M(+21.5%) |
| Mar 2012 | - | -$8.49 M(+19.1%) | -$27.37 M(+20.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$22.80 M(+31.5%) | -$7.12 M(+7.7%) | -$22.80 M(+18.0%) |
| Sep 2011 | - | -$6.61 M(+28.5%) | -$19.32 M(+10.8%) |
| Jun 2011 | - | -$5.15 M(+31.7%) | -$17.44 M(+5.7%) |
| Mar 2011 | - | -$3.91 M(+7.1%) | -$16.50 M(-4.8%) |
| Dec 2010 | -$17.33 M(+22.6%) | -$3.65 M(-22.9%) | -$17.33 M(+4.0%) |
| Sep 2010 | - | -$4.73 M(+12.6%) | -$16.66 M(+12.5%) |
| Jun 2010 | - | -$4.20 M(-11.5%) | -$14.81 M(-5.5%) |
| Mar 2010 | - | -$4.75 M(+59.3%) | -$15.67 M(+10.8%) |
| Dec 2009 | -$14.14 M(-1.8%) | -$2.98 M(+3.3%) | -$14.14 M(+4.1%) |
| Sep 2009 | - | -$2.88 M(-43.0%) | -$13.59 M(-12.5%) |
| Jun 2009 | - | -$5.06 M(+57.1%) | -$15.52 M(+6.0%) |
| Mar 2009 | - | -$3.22 M(+32.7%) | -$14.64 M(+1.7%) |
| Dec 2008 | -$14.40 M(+13.4%) | -$2.43 M(-49.6%) | -$14.40 M(+0.8%) |
| Sep 2008 | - | -$4.82 M(+15.3%) | -$14.28 M(+14.6%) |
| Jun 2008 | - | -$4.18 M(+40.4%) | -$12.46 M(-0.1%) |
| Mar 2008 | - | -$2.98 M(+28.7%) | -$12.47 M(-1.8%) |
| Dec 2007 | -$12.69 M(+18.4%) | -$2.31 M(-22.8%) | -$12.69 M(-6.4%) |
| Sep 2007 | - | -$2.99 M(-28.5%) | -$13.56 M(+3.1%) |
| Jun 2007 | - | -$4.19 M(+30.9%) | -$13.15 M(+11.6%) |
| Mar 2007 | - | -$3.20 M(+0.7%) | -$11.78 M(+10.0%) |
| Dec 2006 | -$10.72 M(+17.4%) | -$3.18 M(+22.9%) | -$10.72 M(+9.7%) |
| Sep 2006 | - | -$2.58 M(-8.6%) | -$9.77 M(-4.9%) |
| Jun 2006 | - | -$2.83 M(+32.6%) | -$10.27 M(+6.3%) |
| Mar 2006 | - | -$2.13 M(-4.2%) | -$9.66 M(+5.8%) |
| Dec 2005 | -$9.13 M(+28.5%) | -$2.22 M(-28.0%) | -$9.13 M(+25.0%) |
| Sep 2005 | - | -$3.09 M(+39.5%) | -$7.30 M(+1.8%) |
| Jun 2005 | - | -$2.21 M(+38.3%) | -$7.18 M(-6.1%) |
| Mar 2005 | - | -$1.60 M(+298.1%) | -$7.64 M(+7.6%) |
| Dec 2004 | -$7.10 M(+81.2%) | -$401.90 K(-86.4%) | -$7.10 M(-4.5%) |
| Sep 2004 | - | -$2.96 M(+10.6%) | -$7.44 M(+37.6%) |
| Jun 2004 | - | -$2.68 M(+152.2%) | -$5.40 M(+29.4%) |
| Mar 2004 | - | -$1.06 M(+43.8%) | -$4.18 M(+6.5%) |
| Dec 2003 | -$3.92 M(-15.2%) | -$737.90 K(-20.4%) | -$3.92 M(+5.6%) |
| Sep 2003 | - | -$927.30 K(-36.0%) | -$3.71 M(-35.7%) |
| Jun 2003 | - | -$1.45 M(+80.0%) | -$5.77 M(+53.2%) |
| Mar 2003 | - | -$804.80 K(+51.8%) | -$3.77 M(-18.5%) |
| Dec 2002 | -$4.62 M(+67.5%) | -$530.00 K(-82.3%) | -$4.62 M(-5.9%) |
| Sep 2002 | - | -$2.99 M(-637.9%) | -$4.91 M(+92.2%) |
| Jun 2002 | - | $555.80 K(-133.5%) | -$2.56 M(-30.1%) |
| Mar 2002 | - | -$1.66 M(+102.9%) | -$3.65 M(+32.4%) |
| Dec 2001 | -$2.76 M(+29.8%) | -$817.70 K(+28.9%) | -$2.76 M(+2.0%) |
| Sep 2001 | - | -$634.20 K(+16.9%) | -$2.71 M(-12.0%) |
| Jun 2001 | - | -$542.30 K(-29.2%) | -$3.07 M(+12.7%) |
| Mar 2001 | - | -$765.70 K(+0.2%) | -$2.73 M(+28.2%) |
| Dec 2000 | -$2.13 M(+491.3%) | -$764.20 K(-23.7%) | -$2.13 M(+56.1%) |
| Sep 2000 | - | -$1.00 M(+413.2%) | -$1.36 M(+278.0%) |
| Jun 2000 | - | -$195.30 K(+18.2%) | -$360.50 K(+118.2%) |
| Mar 2000 | - | -$165.20 K | -$165.20 K |
| Dec 1999 | -$359.70 K | - | - |
FAQ
- What is Oncolytics Biotech annual cash flow from operations?
- What is the all time high annual CFO for Oncolytics Biotech?
- What is Oncolytics Biotech annual CFO year-on-year change?
- What is the all time high quarterly CFO for Oncolytics Biotech?
- What is the all time high TTM CFO for Oncolytics Biotech?
What is Oncolytics Biotech annual cash flow from operations?
The current annual CFO of ONCY is -$21.07 M
What is the all time high annual CFO for Oncolytics Biotech?
Oncolytics Biotech all-time high annual cash flow from operations is -$359.70 K
What is Oncolytics Biotech annual CFO year-on-year change?
Over the past year, ONCY annual cash flow from operations has changed by -$3.12 M (-17.37%)
What is the all time high quarterly CFO for Oncolytics Biotech?
Oncolytics Biotech all-time high quarterly cash flow from operations is $555.80 K
What is the all time high TTM CFO for Oncolytics Biotech?
Oncolytics Biotech all-time high TTM cash flow from operations is -$165.20 K